COVID-19-We urgently need to start developing an exit strategy.


Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 13 04 2020
accepted: 14 04 2020
pubmed: 4 5 2020
medline: 29 7 2020
entrez: 4 5 2020
Statut: ppublish

Résumé

The purpose of this perspective is to review the options countries have to exit the draconian "lockdowns" in a carefully staged manner. Experts from different countries experiencing Corona Virus Infectious Disease 2019 (COVID-19) reviewed evidence and country-specific approaches and the results of their interventions. Three factors are essential: 1. Reintroduction from countries with ongoing community transmission; 2. The need for extensive testing capacity and widespread community testing, and 3. An adequate supply of personal protective equipment, PPE, to protect health care workers. Discussed at length are lifting physical distancing, how to open manufacturing and construction, logistics, and the opening of higher educational institutions and schools. The use of electronic surveillance is considered. Each country should decide on the best path forward. However, we can learn from each other, and the approaches are, in reality, very similar.

Identifiants

pubmed: 32360552
pii: S1201-9712(20)30251-4
doi: 10.1016/j.ijid.2020.04.035
pmc: PMC7188647
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

233-239

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Références

Infect Control Hosp Epidemiol. 2020 May;41(5):493-498
pubmed: 32131908
MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):307-311
pubmed: 32191691
Lancet. 2020 Mar 21;395(10228):945
pubmed: 32142626
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):419-421
pubmed: 32271724
Int J Infect Dis. 2020 May;94:88-90
pubmed: 32305518
J Travel Med. 2020 May 18;27(3):
pubmed: 32167146
Osong Public Health Res Perspect. 2015 Aug;6(4):269-78
pubmed: 26473095
Lancet Infect Dis. 2020 Jul;20(7):793-802
pubmed: 32247326
Korean J Intern Med. 2018 Mar;33(2):233-246
pubmed: 29506344
Int J Biol Sci. 2020 Mar 15;16(10):1698-1707
pubmed: 32226287
Lancet. 2020 Apr 4;395(10230):1101-1102
pubmed: 32247384
JAMA. 2020 Apr 14;323(14):1341-1342
pubmed: 32125371
Int J Epidemiol. 2020 Aug 1;49(4):1063-1066
pubmed: 32232402
Lancet. 2020 Apr 25;395(10233):1382-1393
pubmed: 32277878
Osong Public Health Res Perspect. 2020 Feb;11(1):60-63
pubmed: 32149043
Lancet. 2020 Mar 14;395(10227):848-850
pubmed: 32151326

Auteurs

Eskild Petersen (E)

Institute for Clinical Medicine, Faculty of Health Sciences, University of Aarhus, Denmark; Department of Molecular Medicine, University of Pavia, Italy; European Society for Clinical Microbiology and Infectious Diseases (ESCMID) Task Force for Emerging Infections. Basel, Switzerland.

Sean Wasserman (S)

Division of Infectious Diseases and HIV Medicine, Department of Medicine, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa.

Shui-Shan Lee (SS)

Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR China.

Unyeong Go (U)

International Tuberculosis Research Center, Changwon-si, Republic of Korea.

Allison H Holmes (AH)

National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, Hammersmith Campus, London, United Kingdom.

Seif Al-Abri (S)

Directorate General for Disease Control and Prevention, Ministry of Health, Oman.

Susan McLellan (S)

Biocontainment Treatment Unit, Biosafety for Research-Related Infectious Pathogens, University of Texas Medical Branch, Galveston, TX, USA.

Lucille Blumberg (L)

National Institute for Communicable Diseases, A Division of the National Health Laboratory Service, Johannesburg, South Africa.

Paul Tambyah (P)

Division of Infectious Disease, Department of Medicine University Medicine Cluster, National University Hospital, Singapore. Electronic address: mdcpat@nus.edu.sg.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH